×

Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
Cardiovascular

Study: Pradaxa reduces stroke and death, but increases GI bleeding compared to warfarin

According to a study from the U.S. Food and Drug Administration (FDA), Pradaxa (dabigatran), in comparison to warfarin, was associated with a lower risk of stroke and death, but an increased risk of major gastrointestinal bleeding. The risk for myocardial infarction was similar for the two drugs. In a statement, the FDA said, “[W]e still consider Pradaxa to have a favorable benefit to risk profile and have made no changes to the current label or recommendations for use.” Read more.


Leave a Reply

You have to agree to the comment policy.

 

Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing

Shares